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A dietary supply of docosahexaenoic acid (DHA, 22:6n-3) during the perinatal period is postulated to 
be important for the neurodevelopmental outcome of children.  This paper reviews the results of 
two large scale intervention trials in which equivalent dietary doses of DHA were assessed.  One trial 
assessed the ex utero effect of DHA supplementation for preterm infants born <33 weeks’ gestation 
while the other trial assessed the in utero effect of DHA supplementation during the second half of 
pregnancy.  Ex utero DHA supplementation, which aimed to achieve the level of DHA accumulation 
that would occur in the womb, appeared more effective in improving the neurodevelopmental 
outcome of preterm children rather than in utero DHA supplementation of unborn infants.  
Significant treatment by sex and treatment by birth weight interactions were noted indicating that 
boys and girls respond differently to DHA supplementation and that birth weight may also be 





The n-3 long chain polyunsaturated fatty acid (LCPUFA), docosahexaenoic acid (DHA, 22:6n-3) is 
rapidly accumulated by the fetus during the last trimester of pregnancy.  Post mortem studies 
indicate that the fetus will accumulate a total of approximately 70mg/day, mostly as DHA, during the 
last trimester of pregnancy [
1 2
].  During this time the brain also undergoes a major growth spurt and 
approximately doubles in size from an estimated 125g to 375g [
3
].  Although the growth and 
composition of the brain continue to develop well into the postnatal period, the last trimester of 
pregnancy is the window in which the brain is growing at the greatest velocity and its composition is 
quickly changing [
4
].  This coupled with the rapid somatic growth and the creation of nutrient body 
stores that also occur in the last trimester highlight the potential importance of ensuring an 
adequate supply of DHA [
5
].  Two scenarios, which represent different extremes, are instructive in 
the requirement for DHA during the perinatal period and its effect on neurodevelopment during 
early childhood.  The first scenario relates to very preterm infants who are denied the opportunity to 
accumulate DHA during most of the last trimester.  Instead they are born early, with immature 
organs and no fat reserves.  It therefore logically follows that preterm infants, particularly those 
born at the earliest gestations would be the infants with the greatest DHA requirements and have 
the most to gain from supplementation.  In contrast, the second scenario relates to singleton infants 
who are born at term, having had the benefit of a full in utero supply of DHA.  The logical 
assumption here is that these infants will have a lower requirement of DHA than their counterparts 
who are born prematurely and any benefit of DHA supplementation during the equivalent period 
(whilst they are in utero) will be more modest than what might be expected in preterm infants.  We 
had an opportunity to assess the validity of these hypotheses by comparing the neurodevelopmental 
outcomes of young children who participated in two trials of DHA supplementation.  The first trial 
(DHA for the Improvement of Neurodevelopmental Outcome in preterm infants, DINO) evaluated 
the neurodevelopmental outcomes at 18 months corrected age of preterm infants born before 33 
weeks’ gestation who were fed a standard dose of DHA (about 0.3% of total fatty acids) during the 
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neonatal period compared with a dose of DHA (about 1% of total fatty acids) designed to mimic the 
accumulation of DHA that would have occurred in the womb [
6
]; while the second trial (DHA to 
Optimise Mother Infant Outcome, DOMInO) evaluated neurodevelopment of largely term born 
children at 18 months of age who were either exposed to extra DHA through maternal 
supplementation during the second half of pregnancy or received the natural delivery of DHA across 
the placenta [
7
].  In essence the high DHA treatment group of the DINO trial was attempting to 
mimic that control group of the DOMInO trial.   
Methods of the DINO and DOMInO trials 
The DINO trial was designed to be inclusive of as many infants as possible born <33 weeks’ gestation 
and included infants fed breast milk and infant formula.  Infants were only excluded if they had 
major congenital or chromosomal abnormalities; they were from a multiple birth where not all live 
infants were eligible; in other trials of fatty acid supplementation; or had a mother expressing breast 
milk with a contraindication to taking tuna oil (bleeding disorders, anticoagulants).  Lactating women 
were randomly allocated to take six 500 mg DHA-rich tuna oil capsules per day or six 500 mg placebo 
soy oil capsules.  If formula was required, infants were given a preterm formula with a matching DHA 
composition.  The dietary intervention resulted in infants randomly allocated to higher-DHA 
receiving a DHA concentration triple that of infants allocated to standard-DHA, AA remaining 
constant between the two groups [
6
].  The DHA concentration in the diet of neonates in the higher-
DHA group was approximately 0.9% of total fatty acids while the standard DHA group received milk 
with about 0.3% DHA as total fatty acids.  Parents, clinicians and all research personnel were blinded 
to participant study group.  97% (614 of 632) of all live children at 18 months corrected age were 
assessed using the Bayley Scales of Infant Development, Second Edition (BSID-II).  The Mental 
Development Index (MDI) which evaluates memory, habituation, problem solving, early number 
concepts and language was the primary outcome.   
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The DOMInO trial included women with singleton pregnancies with no known fetal abnormalities at 
study entry (18-21 weeks gestation).  Women were randomly allocated to take 3 x 0.5g capsules per 
day containing either high-DHA fish oil or a blend of three vegetable oils from mid-pregnancy until 
birth.  In total 2399 women and their children from 5 perinatal centres around Australia were 
recruited to allow for two primary outcomes; postnatal depression in the women and cognitive 
development during early childhood [
7
].  The Bayley Scales of Infant and Toddler Development, Third 
edition (Bayley-III) was used to assess neurodevelopment at 18 months of age.  The Cognitive and 
Language Composite Scales were considered primary outcomes for the neurodevelopmental 
assessment.  The cognitive scale evaluates abilities such as sensorimotor development, exploration 
and manipulation, object relatedness, concept formation, memory, and simple problem solving, 
while the language scale is a composite of receptive communication (verbal comprehension, 
vocabulary) and expressive communication (babbling, gesturing, and utterances).  Infants who were 
enrolled in Adelaide were randomly selected for the Bayley-III assessment.  96% (694 of 726) of 
children selected for neurodevelopmental assessment completed the tasks.  
Results of the DINO and DOMInO trials  
Success of intervention 
The success of the DHA interventions in the DINO and DOMInO trials were evident from the DHA 
concentrations in the plasma phospholipid fatty acids of the neonatal blood at 40 weeks post-
menstrual age (when the preterm infants were due to be born) and the cord blood at birth, 
respectively.  As would be expected the DHA status of the preterm infants fed milk (breast milk of 
infant formula) with a standard concentration of DHA (about 0.3% total fatty acids) was low 
compared with DHA supplementation (about 0.9% total fatty acids, see figure 1a).  Although this 
level of DHA supplementation in the DINO trial was designed to match the degree of in utero 
accumulation of DHA, the concentration of DHA in plasma phospholipids at 40 weeks post menstrual 
age was not quite comparable with the plasma phospholipid DHA concentration in cord blood from 
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term births suggesting that the target of DHA supplementation in the DINO trial was not quite 
achieved.  However, the direct comparison of phospholipid fatty acids from neonatal peripheral 
blood at 40 weeks post menstrual age with cord blood at term may have limitations as the 
haemodynamic characteristics are likely to be quite different.  For example, cord blood contains a 
significant proportion of fetal red cells while peripheral blood 10-12 weeks post birth, even from 
preterm infants who were born 28-30 weeks’ gestation, will contain predominantly mature red cells.  
Nevertheless, these comparisons provide a useful guideline regarding the success of 
supplementation.  Interestingly, supplementation of pregnant women with 800mg DHA per day for 
the second half of gestation in the DOMInO trial demonstrated about a 20% increase in the mean 
DHA concentration in cord plasma phospholipid fatty acids (see figure 1b).  Collectively, these data 
provide a basis for understanding the requirement of DHA during the vulnerable perinatal period 
with regards to neurodevelopmental outcomes.      
Neurodevelopmental outcome in early childhood 
Although different version of the Bayley’s Scales were used to assess neurodevelopmental outcomes 
in the DINO and DOMInO trials, the developmental quotient (DQ) scores are nevertheless instructive 
as the assessments in both versions are based on similar tasks and the scoring has been standardised 
to a mean of 100 with a standard deviation of 15 (range from 50 to 150).  In this regard it is 
interesting to note that the mean DQ score on the mental/cognitive scale for preterm children in 
DINO was approximately 94 while the mean DQ for the term children in DOMInO was approximately 
102.  This difference in DQ between preterm children and their counterparts born at term is well 
established in the literature, particularly when considering the most vulnerable preterm children 
born <33 weeks’ as included in DINO [
8
].  Supplementation with higher dose DHA in the DINO trial 
resulted in a non-significant increase in mean DQ compared with the standard dose of DHA, while 
DHA supplementation during pregnancy in the DOMInO trial resulted in no change in the mean 
cognitive DQ (Figure 2 a-b).  However, in both cases these non-significant differences in the mean 
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DQs were associated with significant reductions in the proportion of young children with delayed 
cognitive development with DHA supplementation regardless of whether supplementation occurred 
during the neonatal period for preterm infants or while in utero for those infants born largely at 
term (Figure 3 a-d).  The reduction in the percentage of young children with delayed cognitive 
development at 18 months was most notable in preterm children because of the relatively high 
proportion of children with delayed development and the halving of the number of children with 
severely delayed development (DQ <70, 2SD below the standardised population mean) in the higher-
DHA group (Figure 3c, RR 0.50, 95% CI 0.26 to 0.93; P=0.03).  It was interesting to note that there 
was no effect of DHA supplementation on the high performing side of the distribution and that there 
was no increase in the proportion of children with advanced development in either the DINO or the 
DOMInO trials.  Additionally, the cognitive scores of the children in the DOMInO trial (regardless of 
supplementation) were close to or better than what would be expected for a normal population.  
Collectively these data suggest that any effect of DHA supplementation during the perinatal period 
on early childhood neurodevelopment may be confined to children on the lower performing end of 
the normal distribution and that DHA supplementation during the perinatal period will not result in 
children with advanced cognitive scores.  This also raises the possibility that there may be specific 
subgroups that may benefit from supplementation while others do not respond, perhaps because of 
their adequate DHA status. 
Differential response to DHA supplementation: sex 
One of the most controversial and topical issues to recently emerge is whether boys and girls have 
different DHA requirements and therefore respond different to DHA supplementation.  Previous 
studies have consistently documented the slower and poorer neurodevelopmental scores of boys 
compared with girls in early childhood, particularly in preterm children [
9 10
].  This together with the 
metabolic suggestion that females may more efficiently synthesise DHA from precursor fatty acids 
than males led to the hypothesis that boys may benefit from DHA supplementation more than girls.  
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Both the DINO and DOMInO trials were specifically designed and powdered to address whether 
there were differential effects of DHA supplementation on cognitive development scores according 
to infant sex.  In DOMInO there was no interaction between dietary treatment and sex indicating no 
differential response between boys and girls of DHA supplementation during pregnancy [
7
].  
Conversely in the DINO trial a significant interaction between higher-DHA treatment and sex was 
noted indicating that girls and boys responded differently to DHA treatment.  Higher-DHA 
significantly improved the mean mental/cognitive development of girls (RR 4.5; 95% CI 0.5 to 8.5; P= 
0.03) and reduced mild (DQ score<85) and severe (DQ score<70) cognitive delay (RR 0.43, 95% CI 
0.23 to 0.80; P=0.01 and RR 0.17, 95% CI 0.04 to 0.72; P=0.02 respectively), while no effect of higher-
DHA was noted in boys [
6
].    
Differential response to DHA supplementation: birth weight 
The vast majority of term infants are born with birth weights >2500g having had the benefit of a 
normal in utero supply of DHA across the placenta, while for preterm infants their birth weights can 
vary from <1000g to about 2000g largely depending on their gestational age at birth.  As already 
noted, the neurodevelopmental outcomes of normal weight term children are significantly better 
than their counterparts who are born preterm with lower DHA status.  What has not been well 
studied is whether there is a specific dietary requirement for DHA for term children who are growth 
restricted in utero and generally do not achieve birth weights >2500g.   
For preterm infants in the DINO trial, we had pre-planned analyses to assess whether there was a 
differential effect of higher dietary DHA in the birth weight randomisation strata (<1250g and 
≥1250g).  We did indeed observe an interaction effect which demonstrated that infants born 
weighing <1250g and fed the higher DHA diet had a 4-point improvement in mental development 
scores compared with control, while the mental development scores of infants born weighing 
≥1250g did not differ between groups [
6
].  Similarly the risk of mild mental delay (DQ <85) was 
decreased in infants born weighing <1250g (RR 0.57, 95% CI 0.36 to 0.91; P=0.02), while there was 
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no difference between the groups in infants born weighing ≥1250g [
6
].  Collectively these data 
indicate that infants born weighing <1250g may have the highest DHA requirements and therefore 
showing responsiveness to tests assessing neurodevelopmental outcomes.       
Although this paper highlights that infant sex and infant birth weight may be two characteristics of 
an individual that may modulate the response to DHA supplementation, further work is needed to 
substantiate these findings and to also explore and understand how other biological and socio-
demographic variables affect the DHA requirement during the perinatal period. 
Summary and Conclusions  
The two studies reviewed here were focussed on assessing the effect of in utero and ex utero DHA 
supplementation during roughly the same time period, that of the last trimester of pregnancy. Ex 
utero DHA supplementation targeted at achieving the level of DHA accumulation that would occur in 
the womb appeared more effective in improving the neurodevelopmental outcome of preterm 
children rather than in utero DHA supplementation of unborn infants.  This is perhaps not surprising 
when one considers that infants who are born healthy and at term have had the full benefit of an 
uninterrupted DHA supply across the placenta together with other necessary nutrients.  
Furthermore this nutritional supply is subject to a number of physiological adaptations that are all 
aimed at maintaining nutrient delivery to the fetus often at the expense of the maternal 
requirement.  Nevertheless our data have also highlighted that there are children who are 
responsive to DHA supplementation regardless of whether it was delivered in utero or ex utero and 
further work is needed to better define the sub-groups of children who will benefit from 
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